Should Biogen Investors Be Extra Nervous Right Now?

It seems like Biogen (NASDAQ: BIIB) just can't catch a break. In March, the biotech giant's late-stage Alzheimer's disease program imploded and now the only product pushing the needle forward is under an economic microscope.